1887

Abstract

Vaccination with heat-killed (HKY) protects against experimental infection by pathogenic fungi of five genera. Here we tested whether purified cell wall β-glucan could induce protection against systemic aspergillosis. CD-1 mice were given three weekly vaccine doses subcutaneously prior to intravenous infection with . Mice received PBS, 2.5 mg HKY, whole glucan particles (WGP), WGP conjugated to BSA (0.06 to 12 mg per dose), a soluble medium molecular mass (MMW) β-glucan alone or MMW–BSA (≤24 mg per dose). Survival and c.f.u. were determined, and cytokine induction and anti-β-glucan antibodies were assessed in vaccinated mice. Neither soluble MMW glucan, nor MMW–BSA was effective. HKY protected in two studies (survival and c.f.u. were reduced in brain and kidney organs, <0.004). Six or 12 mg WGP or WGP–BSA prolonged survival (≤0.004) and reduced c.f.u. in each organ (≤0.015) in both experiments; 0.6 mg WGP or WGP–BSA prolonged survival (≤0.015) and reduced c.f.u. (≤0.015) in one experiment. Cytokine profiles in serum and bronchoalveolar lavage from uninfected vaccinated mice showed an innate and adaptive immune profile (i.e. upregulation of colony stimulating factors, interferons, TNF-α, chemokines such as MCP-1, MIP-1α, RANTES and KC, and Th17-activating cytokines such as IL-6, IL-1β, IL-17). No anti-β-glucan antibodies were in the sera, suggesting an adaptive T cell-mediated, not a B cell-mediated, protective response. Vaccination with WGP or WGP–BSA proved protective against systemic aspergillosis, equivalent to that of HKY, supporting the potential of particulate β-glucans, alone or conjugated, as vaccines against aspergillosis.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.079681-0
2014-12-01
2019-11-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/12/1750.html?itemId=/content/journal/jmm/10.1099/jmm.0.079681-0&mimeType=html&fmt=ahah

References

  1. Ahmad S., Tester R. F., Corbett A., Karkalas J.. ( 2006;). Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. . Carbohydr Res 341:, 2694–2701. [CrossRef][PubMed]
    [Google Scholar]
  2. Bailey R. W.. ( 1958;). The reaction of pentoses with anthrone. . Biochem J 68:, 669–672.[PubMed]
    [Google Scholar]
  3. Bozza S., Gaziano R., Lipford G. B., Montagnoli C., Bacci A., Di Francesco P., Kurup V. P., Wagner H., Romani L.. ( 2002;). Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. . Microbes Infect 4:, 1281–1290. [CrossRef][PubMed]
    [Google Scholar]
  4. Bystrický S., Machová E., Bartek P., Kolarova N., Kogan G.. ( 2000;). Conjugation of yeast mannans with protein employing cyanopyridinium agent (CDAP) – an effective route of antifungal vaccine preparation. . Glycoconj J 17:, 677–680. [CrossRef][PubMed]
    [Google Scholar]
  5. Capilla J., Clemons K. V., Liu M., Levine H. B., Stevens D. A.. ( 2009;). Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. . Vaccine 27:, 3662–3668. [CrossRef][PubMed]
    [Google Scholar]
  6. Cassone A., Torosantucci A.. ( 2006;). Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. . Expert Rev Vaccines 5:, 859–867. [CrossRef][PubMed]
    [Google Scholar]
  7. Cenci E., Mencacci A., Bacci A., Bistoni F., Kurup V. P., Romani L.. ( 2000;). T cell vaccination in mice with invasive pulmonary aspergillosis. . J Immunol 165:, 381–388. [CrossRef][PubMed]
    [Google Scholar]
  8. Clemons K. V., Antonysamy M. A., Danielson M. E., Michel K. S., Martinez M., Chen V., Stevens D. A.. ( 2014;). Whole glucan particles (WGP) as a vaccine against systemic coccidioidomycosis. . In Interscience Conference on Antimicrobial Agents Chemotherapy, abstract G-1894. Washington, DC:: American Society for Microbiology;.
    [Google Scholar]
  9. Committee for the update of the Guide for the Care and Use of Laboratory Animals ( 2011;). Guide for the Care and Use of Laboratory Animals, , 8th edn.. Washington, DC:: The National Academies Press;.
    [Google Scholar]
  10. Danielson M. E., Dauth R., Elmasry N. A., Langeslay R. R., Magee A. S., Will P. M.. ( 2010;). Enzymatic method to measure β-1,3-β-1,6-glucan content in extracts and formulated products (GEM assay). . J Agric Food Chem 58:, 10305–10308. [CrossRef][PubMed]
    [Google Scholar]
  11. Dasbach E. J., Davies G. M., Teutsch S. M.. ( 2000;). Burden of aspergillosis-related hospitalizations in the United States. . Clin Infect Dis 31:, 1524–1528. [CrossRef][PubMed]
    [Google Scholar]
  12. Denning D. W., Stevens D. A.. ( 1991;). Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. . Antimicrob Agents Chemother 35:, 1329–1333. [CrossRef][PubMed]
    [Google Scholar]
  13. Hanson L. H., Clemons K. V., Denning D. W., Stevens D. A.. ( 1995;). Efficacy of oral saperconazole in systemic murine aspergillosis. . J Med Vet Mycol 33:, 311–317. [CrossRef][PubMed]
    [Google Scholar]
  14. Herbrecht R., Denning D. W., Patterson T. F., Bennett J. E., Greene R. E., Oestmann J. W., Kern W. V., Marr K. A., Ribaud P.. & other authors ( 2002;). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. . N Engl J Med 347:, 408–415. [CrossRef][PubMed]
    [Google Scholar]
  15. Hong F., Yan J., Baran J. T., Allendorf D. J., Hansen R. D., Ostroff G. R., Xing P. X., Cheung N. K., Ross G. D.. ( 2004;). Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. . J Immunol 173:, 797–806. [CrossRef][PubMed]
    [Google Scholar]
  16. Huang H., Ostroff G. R., Lee C. K., Wang J. P., Specht C. A., Levitz S. M.. ( 2009;). Distinct patterns of dendritic cell cytokine release stimulated by fungal β-glucans and Toll-like receptor agonists. . Infect Immun 77:, 1774–1781. [CrossRef][PubMed]
    [Google Scholar]
  17. Huang H., Ostroff G. R., Lee C. K., Agarwal S., Ram S., Rice P. A., Specht C. A., Levitz S. M.. ( 2012;). Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans. . J Immunol 189:, 312–317. [CrossRef][PubMed]
    [Google Scholar]
  18. Hurtgen B. J., Hung C. Y., Ostroff G. R., Levitz S. M., Cole G. T.. ( 2012;). Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis. . Infect Immun 80:, 3960–3974. [CrossRef][PubMed]
    [Google Scholar]
  19. Ito J. I., Lyons J. M.. ( 2002;). Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. . J Infect Dis 186:, 869–871. [CrossRef][PubMed]
    [Google Scholar]
  20. Ito J. I., Lyons J. M., Hong T. B., Tamae D., Liu Y. K., Wilczynski S. P., Kalkum M.. ( 2006;). Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. . Infect Immun 74:, 5075–5084. [CrossRef][PubMed]
    [Google Scholar]
  21. Lachin J. M.. ( 1999;). Worst-rank score analysis with informatively missing observations in clinical trials. . Control Clin Trials 20:, 408–422. [CrossRef][PubMed]
    [Google Scholar]
  22. Liu M., Clemons K., Bystricky S., Stevens D.. ( 2010;). Glycans and conjugates as vaccines against coccidioidomycosis. . In 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract G1-1657. Washington, DC:: American Society for Microbiology;.
    [Google Scholar]
  23. Liu M., Capilla J., Johansen M. E., Alvarado D., Martinez M., Chen V., Clemons K. V., Stevens D. A.. ( 2011a;). Saccharomyces as a vaccine against systemic aspergillosis: ‘the friend of man’ a friend again. ? J Med Microbiol 60:, 1423–1432. [CrossRef][PubMed]
    [Google Scholar]
  24. Liu M., Clemons K. V., Bigos M., Medovarska I., Brummer E., Stevens D. A.. ( 2011b;). Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. . Vaccine 29:, 1745–1753. [CrossRef][PubMed]
    [Google Scholar]
  25. Liu M., Clemons K. V., Johansen M. E., Martinez M., Chen V., Stevens D. A.. ( 2012a;). Saccharomyces as a vaccine against systemic candidiasis. . Immunol Invest 41:, 847–855. [CrossRef][PubMed]
    [Google Scholar]
  26. Liu M., Machová E., Neščáková Z., Medovarská I., Clemons K. V., Martinez M., Chen V., Bystrický S., Stevens D. A.. ( 2012b;). Vaccination with mannan protects mice against systemic aspergillosis. . Med Mycol 50:, 818–828. [CrossRef][PubMed]
    [Google Scholar]
  27. Luo G., Gebremariam T., Clemons K. V., Stevens D. A., Ibrahim A. S.. ( 2014;). Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. . Vaccine 32:, 3573–3576. [CrossRef][PubMed]
    [Google Scholar]
  28. Luque J. C., Clemons K. V., Stevens D. A.. ( 2003;). Efficacy of micafungin alone or in combination against systemic murine aspergillosis. . Antimicrob Agents Chemother 47:, 1452–1455. [CrossRef][PubMed]
    [Google Scholar]
  29. Magee A., Rolke J., Yang R., Gerstner J.. ( 2007;). Glucan preparations. International Patent Application WO2007/146416 A2. .
    [Google Scholar]
  30. Majumder T., Liu M., Chen V., Martinez M., Alvarado D., Clemons K. V., Stevens D. A.. ( 2014;). Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii. . Mycopathologia 178:, 189–195. [CrossRef][PubMed]
    [Google Scholar]
  31. Manners D. J., Masson A. J., Patterson J. C.. ( 1973;). The structure of a β-(1→3)-D-glucan from yeast cell walls. . Biochem J 135:, 19–30.[PubMed]
    [Google Scholar]
  32. Marr K. A., Patterson T., Denning D.. ( 2002;). Aspergillosis: pathogenesis, clinical manifestations, and therapy. . Infect Dis Clin North Am 16:, 875–894. [CrossRef][PubMed]
    [Google Scholar]
  33. Nanjappa S. G., Heninger E., Wüthrich M., Gasper D. J., Klein B. S.. ( 2012;). Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. . PLoS Pathog 8:, e1002771. [CrossRef][PubMed]
    [Google Scholar]
  34. Pelizon A. C., Kaneno R., Soares A. M., Meira D. A., Sartori A.. ( 2005;). Immunomodulatory activities associated with β-glucan derived from Saccharomyces cerevisiae. . Physiol Res 54:, 557–564.[PubMed]
    [Google Scholar]
  35. Shih W.. ( 2002;). Problems in dealing with missing data and informative censoring in clinical trials. . Curr Control Trials Cardiovasc Med 3:, 4. [CrossRef][PubMed]
    [Google Scholar]
  36. Soltanian S., Stuyven E., Cox E., Sorgeloos P., Bossier P.. ( 2009;). β-glucans as immunostimulant in vertebrates and invertebrates. . Crit Rev Microbiol 35:, 109–138. [CrossRef][PubMed]
    [Google Scholar]
  37. Steinbach W. J., Stevens D. A.. ( 2003;). Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. . Clin Infect Dis 37: (Suppl. 3), S157–S187. [CrossRef][PubMed]
    [Google Scholar]
  38. Stevens D. A.. ( 2000;). Aspergillosis. . In Cecil Textbook of Medicine, pp. 1875–1877. Edited by Goldman L., Bennett J. C... Philadelphia:: W.B. Saunders;.
    [Google Scholar]
  39. Stevens D. A.. ( 2004;). Vaccinate against aspergillosis! A call to arms of the immune system. . Clin Infect Dis 38:, 1131–1136. [CrossRef][PubMed]
    [Google Scholar]
  40. Stevens D. A., Clemons K. V., Liu M.. ( 2011;). Developing a vaccine against aspergillosis. . Med Mycol 49: (Suppl. 1), S170–S176. [CrossRef][PubMed]
    [Google Scholar]
  41. Sugar A. M., Brummer E., Stevens D. A.. ( 1983;). Murine pulmonary macrophages: evaluation of lung lavage fluids, miniaturized monolayers, and candidacidal activity. . Am Rev Respir Dis 127:, 110–112.[PubMed]
    [Google Scholar]
  42. Tian J., Ma J., Ma K., Ma B., Tang X., Baidoo S. E., Tong J., Yan J., Lu L.. & other authors ( 2012;). Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma. . PLoS ONE 7:, e46936. [CrossRef][PubMed]
    [Google Scholar]
  43. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., Norelli F., Bellucci C., Polonelli L.. & other authors ( 2005;). A novel glyco-conjugate vaccine against fungal pathogens. . J Exp Med 202:, 597–606. [CrossRef][PubMed]
    [Google Scholar]
  44. Torosantucci A., Chiani P., Bromuro C., De Bernardis F., Palma A. S., Liu Y., Mignogna G., Maras B., Colone M.. & other authors ( 2009;). Protection by anti-β-glucan antibodies is associated with restricted β-1,3 glucan binding specificity and inhibition of fungal growth and adherence. . PLoS ONE 4:, e5392. [CrossRef][PubMed]
    [Google Scholar]
  45. Warnock D. W.. ( 2006;). Fungal diseases: an evolving public health challenge. . Med Mycol 44:, 697–705. [CrossRef][PubMed]
    [Google Scholar]
  46. Wuthrich M., Filutowicz H. I., Warner T., Deepe G. S. Jr, Klein B. S.. ( 2003;). Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. . J Exp Med 197:, 1405–1416. [CrossRef][PubMed]
    [Google Scholar]
  47. Yan J., Allendorf D. J., Brandley B.. ( 2005;). Yeast whole glucan particle (WGP) β-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. . Expert Opin Biol Ther 5:, 691–702. [CrossRef][PubMed]
    [Google Scholar]
  48. York W. S., Darvill A. G., McNeil M., Stevenson T. T., Albersheim P.. ( 1986;). Isolation and characterization of plant cell walls and cell wall components. . Methods Enzymol 118:, 3–40. [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.079681-0
Loading
/content/journal/jmm/10.1099/jmm.0.079681-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error